RAMB - Maio / Junho 2016

alcoholic

fatty

liver

disease

(NAFLD)

different

populations

: A

clinical

and

epidemiological

study

–

sample

ão

osé

reto

ssoc

ras

2016; 62(3):218-226

225

tose e esteato-hepatite não alcoólica (NASH), na ausên-

cia de consumo significante de álcool, podendo atingir

30% da população. Fatores de risco mais comuns são ida-

de, gênero, etnia,

diabetes mellitus

(DM), obesidade, predis-

posição, síndrome matabólica (SM), resistência à insuli-

na (RI), drogas e síndrome do ovário policístico.

Objetivo:

descrever o perfil de portadores de DHGNA as-

sistidos no Hospital de Base de São José do Rio Preto, SP.

Método:

foram avaliados pacientes com DHGNA e cole-

tados dados clínico-epidemiológicos, após consentimen-

to informado.

Resultados:

dos 62 pacientes estudados, houve predo-

mínio de mulheres (76%), caucasoides (73%), idade entre

a quinta e sexta décadas e assintomáticos (71%). Exame

de ultrassonografia (US) mostrou esteatose em 84%. NASH

foi diagnosticada em 61% da casuística. Em 21 pacientes,

biópsia hepática mostrou cirrose em 36% e câncer de fí-

gado e esteatose pura em um paciente (5%) cada. Dos fa-

tores de risco, 70% dos pacientes apresentavam SM; 87%,

cintura abdominal alterada; 63%, dislipidemia; 61% (n=38),

hipertensão arterial sistêmica (HAS); 28%, DM; 52%, se-

dentarismo, e em 44% encontrou-se RI (HOMA>3,5). Hou-

ve associação entre RI e NASH (p=0,013), RI e obesidade

(p=0,027), RI e SM (p=0,006), SM e esteatose à US

(p=0,014).

Conclusão:

os fatores de risco mais frequentes foram SM

e suas variáveis (cintura abdominal aumentada, dislipi-

demia e HAS), o que ressalta a importância do controle

metabólico na DHGNA e corrobora o seu papel como

componente hepático da SM.

Palavras-chave:

fígado gorduroso,

diabetes mellitus

, obe-

sidade.

eferences

1. Adams LA, Lymp JF, Sauver JSP, Sanderson SO, Lindor KD, Feldstein A, et

al. The natural history of nonalcoholic fatty liver disease: a population-

based cohort study. Gastroenterology. 2005; 129(1):113-21.

2. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver

fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;

30(6):1356-62.

3. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment

Pharmacol Ther. 2007; 25(8):883-9.

Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic

steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;

107(4):1103-9.

Bedogni G, Marchesini G, Tiribelli C, Bellentani S, Miglioli L, Masutti F.

Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos

nutrition and liver study. Hepatology. 2005; 42(1):44-52.

Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen

JC, et al. Prevalence of hepatic steatosis in an urban population in the United

States: impact of ethnicity. Hepatology. 2004; 40(6):1387-95.

Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M,

et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective

study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.

BMJ. 2005; 330(7497):932.

Brunt EM, Janney CG, Di Bisceglie AM, Neusechwander-Tetri BA, Bacon

BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the

histological lesions. Am J Gastroenterol. 1999; 94(9):2467-74.

9. Chalasani N. Fatty liver disease as a component of metabolic syndrome.

Hepatology. 2006; 44(Suppl. 1):37A-187A.

10. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis.

Semin Liver Dis. 2001; 21(1):27-41.

11. Cotrim HP, Andrade ZA, Paraná R, Portugal M, Lyra LG, Freitas LA.

Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers. Liver.

1999; 19(4):299-304.

12. Cotrim HP, Freitas LA, Freitas C, Braga L, Paraná R, Lyra L, Carvalho F.

Nonalcoholic steatohepatitis in petrochemical workers: follow up of those

removed from exposure area and those who remained. Hepatology. 2002;

36:983.

13. Cotrim HP, De Freitas LA, Freitas C, Braga L, Carvalho F, Paraná R, et al.

Clinical and histopathological features of NASH in workers exposed to

chemicals with or without associated metabolic conditions. Liver Int. 2004;

24(2):131-5.

14.

Day CP. Natural history of NAFLD: remarkably benign in the absence of

cirrhosis. Gastroenterology. 2005; 129(1):375-8.

15.

Diehl AM, Goodman Z, Ishak KG. Alcoholic liver disease in non-alcoholics.

A clinical and histological comparison with alcohol induced liver injury.

Gastroenterology. 1988; 95(4):1056-62.

16.

Executive Summary of the Third Report of the National Cholesterol

Education Program (NCEP) Expert Panel on Detection, Evaluation, and

Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).

JAMA 2001; 285(19):2486-7.

17.

Falchuk KR, Fiske SC, Haggitt RC, Federman M, Trey C. Pericentral hepatic

fibrosis and intracellular hyaline in diabetes mellitus. Gastroenterology.

1980; 78(3):535-41.

18.

Farrel GC. Drugs and steatohepatitis. Semin Liver Dis. 2002; 22(2):185-94.

19. Gholam PM, Kotler DP, Flancbaum LJ. Liver pathology in morbidly obese

patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg. 2002;

12(1):49-51.

20. Grieco A, Forgione A, Miele L, Vero V, Greco AV, Gasbarrini A, et al. Fatty

liver and drugs. Eur Rev Med Pharmacol Sci. 2005; 9(5):261-3.

21.

Hashimoto E, Yatsuji S, Kaneda H, Yoshioka Y, Taniai M, Tokushige K, et

al. The characteristics and natural history of Japanese patients with

nonalcoholic fatty liver disease. Hepatol Res. 2005; 33(2):72-6.

22. Ong MD, Younossi ZM. Nonalcoholic fatty liver disease (NAFLD) – two

decades later: are we smarter about its natural history? Am J Gastroenterol.

2003; 98(9):1915-7.

23.

Kleiner DE, Brunt EE, Natta MV, Behling C, Contos MJ, Cummings OW, et

al. Design and validation of a histological scoring system for nonalcoholic

fatty liver disease. Hepatology. 2005; 41(6):1313-21.

24.

Lima VMR. Esteatohepatite não-alcoólica (ENA) em camundongos obesos

(ob/ob): avaliação do efeito citoprotetor do Yo Jyo Hen Shi Ko (YHK). São

Paulo: Universidade de São Paulo-USP, 2007.

25.

Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary

syndrome. Ann Intern Med. 2000; 132(12):989-93.

26.

Lonardo A. Fatty liver and nonalcoholic steatohepatitis. Where do we stand

and where are we going? Dig Dis. 1999; 17(2):80-9.

27.

Ludwig J, Viaggiano TR, McGil DB, Oh BJ. Nonalcoholic steatohepatitis:

Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc.

1980; 55(7):434-8.

28.

Machado M, Pinto HC. Non-alcoholic fatty liver disease and insulin resistance.

Eur J Gastroenterol Hepatol. 2005; 17(8):823-6.

29.

Marchesini G, Brizi M, Moreselli-Labate AM, Bianchi G, Bugianesi E,

McCullough AJ, et al. Association of nonalcoholic fatty liver disease with

insulin resistance. Am J Med. 1999; 107(5):450-5.

30.

Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al.

Nonalcoholic fatty liver disease: a feature of metabolic syndrome. Diabetes.

2001; 50(8):1844-50.

31.

Martinez E, Mocroft A, García-Viejo MA, Pérez-Cuevas JB, Blanco JL, Mallolas

J, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease

inhibitors: a prospective cohort study. Lancet. 2001; 357(9256):592-8.

32.

Matteoni CA, Younossi ZM., Gramlich T, Boparai N, Liu YC, McCullough

AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological

severity. Gastroenterology. 1999; 116(6):1413-9.